The MAJIC-PV Study is now completed and the results have been published
Researchers wanted to find out how well Ruxolitinib worked compared with the best available therapy as a treatment for people with PV who were at risk of developing blood clots that could lead to a heart attack or stroke. Specifically, the study looked at people who had already taken Hydroxycarbamide (also known as Hydrea) for their PV, who had either become intolerant to it, meaning that it had stopped working for them, or gave them side effects that made it difficult for them to keep taking it.
The MAJIC-PV Study shows that for people with PV, who cannot take Hydroxycarbamide (Hydrea), Ruxolitinib could help normalize their blood counts and spleen size, improve their PV symptoms, decrease the number of faulty JAK2 genes in their body and reduce their chances of experiencing major medical problems caused by their PV.
You can view a video summary of the MAJIC-PV Study from the author’s perspective (Professor Claire Harrison) here
You can also read a summary of the MAJIC-PV Study here
